dacarbazine has been researched along with carmustine in 291 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 68 (23.37) | 18.7374 |
| 1990's | 58 (19.93) | 18.2507 |
| 2000's | 93 (31.96) | 29.6817 |
| 2010's | 72 (24.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellet, RE; Berd, D; Danna, V; Mastrangelo, MJ | 1 |
| Bast, RC; Borsos, T; Greene, SL; Ohanian, SH; Rapp, HJ; Segerling, M; Zbar, B | 1 |
| McPherson, TA; Paterson, AH; Willans, DJ | 1 |
| Albert, DM; Liu, HS; Perry, HD; Refojo, MF | 1 |
| Bonmassar, E; Goldin, A; Nicolin, A | 1 |
| Kisner, D; MacDonald, JS; Schein, PS | 1 |
| Comis, RL | 1 |
| Hill, G; Johnson, RO; Krementz, E; Metter, G; Wilson, W | 1 |
| Costanzi, JJ | 1 |
| Carbone, PP; Costello, W | 1 |
| Slavik, M | 1 |
| Falkson, G; van Eden, EB | 1 |
| Bellett, RE; Bodurtha, AJ; Laucius, JF; Mastrangelo, MJ | 1 |
| Carter, SK | 1 |
| Levin, VA; Wilson, CB | 1 |
| Cruz, AB; Davis, HL; Fletcher, WS; Golomb, FM; Grage, T; Hill, GJ; Johnson, RO; Metter, G; Wilson, WL | 1 |
| Hersh, EM; Hewlett, JS; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW | 1 |
| Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ | 1 |
| Bodey, GP; Lane, M; Luce, JK; McKelvey, EM; Moon, TE; Talley, RW; Vaitkevicius, VK | 1 |
| Cavalli, M; Goldin, A; Missiroli, A; Nicolin, A | 1 |
| Aranha, GV; Grage, TB | 1 |
| Carter, RD; Fletcher, WS; Golomb, FM; Grage, TB; Hill, GJ; Krementz, ET; Metter, GE; Minton, JP; Sparks, FC | 1 |
| Larsen, V; Pedersen, H; von Eyben, FE | 1 |
| Beretta, G; Bonadonna, G; Cascinelli, N; Morabito, A; Veronesi, U | 1 |
| Biran, S; Brufman, G; Ratzkowski, E | 1 |
| Carmo-Pereira, J; Oliveira Costa, F; Pimentel, P | 1 |
| Cardinali, G; Catalano, G | 1 |
| Falkson, G; Van Dyk, JJ | 1 |
| Luce, JK | 1 |
| Bonmassar, E; Gaston, MR; Goldin, A; Houchens, DP; Kende, M | 1 |
| Kleeberg, UR; Schreml, W | 1 |
| Bosly, A; Doyen, C; Ferrant, A; Machiels, JP; Martiat, P; Michaux, JL | 1 |
| Buzaid, AC; Murren, J | 1 |
| Mehta, N; Ramming, K; Richards, JM; Skosey, P | 1 |
| Cruse, CW; Klein, CJ; Reintgen, DS; Saba, HI; Wells, KE | 2 |
| Glover, DJ | 1 |
| Bastion, Y; Coiffier, B; Tigaud, JD | 1 |
| Basile, M; Bennett, JM; Blumberg, N; Harris, J; Moskowitz, B | 1 |
| Doane, LL; Gilewski, TA; Mitchel, B; Ramming, K; Richards, JM; Vogelzang, NJ | 1 |
| Boaziz, C; Breau, JL; Israël, L; Morere, JF | 1 |
| Bulgarini, B; De Vecchis, L; Giuliani, A; Turriziani, M | 1 |
| Richards, JM | 1 |
| Bizzari, JP; Deloffre, P; Etienne, MC; Fischel, JL; Formento, P; Frenay, M; Gioanni, J; Milano, G | 1 |
| Borri-Voltattorni, C; Dominici, P; Fioretti, MC; Fuschiotti, P; Puccetti, P; Romani, L | 1 |
| Barnett, MJ; Connors, JM; Fay, JW; Herzig, GP; Herzig, RH; Klingemann, HG; Phillips, GL; Reece, DE; Shepherd, JD; Wolff, SN | 1 |
| Dive, C; Watson, JV; Workman, P | 1 |
| Binon, J; Ferrant, A; Hamoir, V; Michaux, JL; Sokal, G | 1 |
| Schoen, HD; Wendt, T | 1 |
| Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF; Sprandio, JD | 1 |
| Al-Sarraf, M; Athens, JW; Costanzi, JJ; Eltringham, JR; Eyre, HJ; Fletcher, WS; Gehan, EA; Oishi, N; Talley, RW; Vogel, FS | 1 |
| Albright, RE; Bullard, DE; Burger, PC; Cairncross, JG; DeLong, ER; Friedman, HS; Khandekar, JD; Mahaley, MS; Schold, SC; Vick, NA | 1 |
| Fioretti, MC; Puccetti, P; Romani, L | 1 |
| Goldin, A; Wittes, RE | 1 |
| Abdi, EA; Hanson, J; McPherson, TA | 1 |
| Bellet, RE; Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
| Balcerzak, SP; Costanzi, JH; Dixon, D; Fabian, CJ; Maloney, T; Neidhart, J; Neilan, B; O'Bryan, RM; Quagliana, J; Tranum, BL | 1 |
| Broggini, M; Catapano, CV; Citti, L; D'Incalci, M; Erba, E; Mariani, L; Ponti, M | 1 |
| Aragon, V; Bröcker, EB; Bünte, H; Czarnetzki, BM; Krieg, V; Macher, E | 1 |
| Creagan, ET; Green, SJ; Long, HJ; Schutt, AJ | 1 |
| Chessa, A; Desogus, A; Floris, C; Muggiano, A; Sulis, E; Tedde, A; Turno, R | 1 |
| Olweny, CL | 1 |
| Cheung, T; Cohen, SM; Holland, JF; Ohnuma, T | 1 |
| Fischer, J; Hinterberger, R; Preiss, J; Weigand, H | 1 |
| Chang, CH; Horton, J; Kramer, S; Nelson, JS; Perez-Tamayo, R; Salazer, O; Schoenfeld, D; Tsukada, Y; Weinstein, A | 1 |
| D'Incalci, M; Damia, G; Erba, E; Garattini, S; Morasca, L; Torti, L | 1 |
| Al-Sarraf, M; Balcerzak, SP; Costanzi, JJ; Eyre, HJ; Fletcher, WS; Frank, J; O'Bryan, RM; Taylor, S | 1 |
| Hill, GJ; Hill, HZ; Krementz, ET | 1 |
| Kendall, AR; Stein, BS | 1 |
| Fuggetta, MP; Giuliani, A; Goldin, A; Guadagni, F; Perno, CF; Roselli, M | 1 |
| Del Prete, SA; Forcier, RJ; LeMarbre, P; Maurer, LH; O'Donnell, J | 1 |
| Klemm-Mayer, H; Rasokat, H; Wagner, G | 1 |
| Atassi, G; Dumont, P; Tagnon, HJ | 1 |
| Canti, G; Goldin, A; Marelli, O; Nicolin, A; Veronese, F | 1 |
| Bonmassar, A; Circolo, A; Contessa, AR; Fioretti, MC; Giampietri, A; Goldin, A | 1 |
| Falkson, G; Falkson, HC | 2 |
| Liter, ME | 1 |
| Gordy, DD; Murray, JL; Robertson, DM; Wilkinson, CP | 1 |
| Bartocci, A; Bonmassar, E; Goldin, A; Puccetti, P; Riccardi, C; Spreafico, F | 1 |
| Dufour, FD; Mah, SG; Morton, DL; Okada, GT | 1 |
| Feun, LG; Hurley, J; Liebmann, A; Moffat, F; Raub, WA; Richman, SP; Robinson, D; Savaraj, N | 1 |
| Algermissen, B; Czarnetzki, BM; Kohlmus, CM; Schadendorf, D; Worm, M | 1 |
| Barnett, MJ; Fairey, RN; Hogge, DE; Klasa, RJ; Klingemann, HG; Nantel, SH; Reece, DE; Shepherd, JD; Sutherland, HJ; Voss, NJ | 1 |
| Atzpodien, J; Chaitchik, S; Duensing, S; Franzke, A; Kirchner, H; Körfer, A; Lopez Hänninen, E; Poliwoda, H; Schomburg, A; Volkenandt, M | 1 |
| Bigner, DD; Catino, JJ; Dolan, ME; Friedman, HS; Keir, S; Marcelli, S; Pegg, AE; Schold, SC | 1 |
| Berd, D; Mastrangelo, MJ | 1 |
| Adkins, DR; Boldt, D; Freytes, CO; Irvin, R; Kuhn, J; LeMaistre, CF; Lyons, R; Roodman, GD; Salzman, D; Smith, L | 1 |
| Dolan, ME; Janisch, L; Mitchell, RB; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Asko-Seljavaara, S; Franssila, K; Kangas, L; Laasonen, A; Muhonen, T; Pyrhönen, S; Wasenius, VM | 1 |
| Grever, MR; Koutsoukos, AD; Moore, TD; Plowman, J; Rubinstein, LV; Waud, WR | 1 |
| McClay, EF; McClay, ME | 1 |
| Becker, JC; Bröcker, EB; Klingert, S; Winkler, B | 1 |
| Losada, R; Meelu, MA; Nathanson, L | 1 |
| Crowell, EB; Higa, GM | 1 |
| Dolan, ME; Mitchell, RB | 1 |
| Appino, A; Bernengo, MG; Bertero, M; Colonna, S; Doveil, GC; Fierro, MT; Novelli, M | 1 |
| Chertoff, J; DelPrete, SA; Ernstoff, MS; Forcier, RJ; Lattanzi, SC; LeMarbre, PJ; Maurer, LH; Mott, L; O'Donnell, J; Tosteson, T | 1 |
| May, BL; Newlands, ES; Porteus, JK; Wedge, SR | 1 |
| Newlands, ES; Wedge, SR | 1 |
| Bresnick, E; Sheng, P; Wang, G; Weiss, C | 1 |
| Armitage, GR; Bennett, K; Bodurtha, AJ; Burdette-Radoux, S; Iscoe, NA; James, KW; Jensen, J; Lohmann, RC; McCulloch, PB; Quirt, IC; Rusthoven, JJ; Silver, HK; Verma, S; Zee, B | 1 |
| Atzpodien, J; Kirchner, HH; Poliwoda, H | 1 |
| Newlands, ES; Porteous, JK; Wedge, SR | 1 |
| Ang, PT; Tan, EH | 1 |
| Gerson, SL; Liu, L; Markowitz, S | 1 |
| Ashby, J; Chinnasamy, N; Dexter, TM; Fairbairn, LJ; Hickson, I; Margison, GP; Rafferty, JA; Tinwell, H | 1 |
| Fefer, A; Gold, PJ; Thompson, JA | 1 |
| Buzaid, AC; Poo, WJ; Schultz, MZ | 1 |
| Byrd, DR; Fefer, A; Gold, PJ; Lindgren, CG; Markowitz, DR; Thompson, JA | 1 |
| Barth, NM; Dillman, RO; Honeycutt, PJ; Schulof, R; Soori, G; Stark, JJ; Wiemann, MC | 1 |
| A'Hern, RP; Atkinson, H; Constenla, DO; Dadian, G; Gore, ME; Johnston, SR; Moore, J; Riches, PG | 1 |
| Berd, D; Mastrangelo, MJ; McClay, EF | 1 |
| Atzpodien, J; Buer, J; Franzke, A; Ganser, A; Hoffmann, R; Kirchner, H; Lassmann, S; Müller, I; Neuber, K; Oevermann, K; Probst, M | 1 |
| Day, R; Donnelly, S; Gerson, SL; Kirkwood, JM; Liu, L; Smith, DC; Trump, DL | 1 |
| Fei, ZL; Gallo, JM; Klein-Szanto, A; Ma, J | 1 |
| Davis, BM; Gerson, SL; Liu, L; Reese, JS | 1 |
| Bernstein, Z; Drumea, K; Haim, N; Shklar, Z; Stein, ME; Steiner, M; Zalik, M | 1 |
| Gale, D; Lestingi, T; Mehta, N; Richards, JM | 1 |
| Allan, JM; Broekhof, JL; Carls, NH; Donker, I; Engelward, BP; Glassner, BJ; Hampson, RJ; Hersmus, R; Hickman, MJ; Hoeijmakers, JH; Roth, RB; Samson, LD; Warren, HB; Weeda, G; Wu, MM | 1 |
| Chatterjee, S; Gerson, SL; Liu, L; Taverna, P; Whitacre, CM | 1 |
| Creagan, ET; Dalton, RJ; Krook, JE; Long, HJ; Michalak, JC; Pitot, HC; Rowland, KM; Suman, VJ; Veeder, MH; Vukov, AM | 1 |
| Agarwala, SS; Begg, CB; Chapman, PB; Destro, AN; Einhorn, LH; Ernstoff, MS; Houghton, AN; Kirkwood, JM; Meyers, ML; Panageas, KS; Saxman, S; Schuchter, LM | 1 |
| Foss, HD; Keilholz, U; Knauf, W; Siehl, J; Szelényi, H; Thiel, E | 1 |
| Ashcroft, L; Harper, P; Lee, SM; Lorigan, P; Middleton, MR; Owen, J; Thatcher, N | 1 |
| Gerson, SL; Koç, ON; Reese, JS | 1 |
| Braybrooke, JP; Christodoulos, K; Ganesan, TS; Han, C; Harris, AL; Levitt, NC; O'Byrne, K; Propper, DJ; Talbot, DC | 1 |
| Cognetti, F; Sega, FM; Serrone, L; Zeuli, M | 1 |
| Adler, A; Rakowsky, E; Schachter, J; Sulkes, A | 1 |
| Prados, MD | 1 |
| Eggermont, AM; Keilholz, U; Suciu, S | 1 |
| Cai, Y; Dolan, ME; Ludeman, SM; Pegg, AE; Wu, MH; Xu-Welliver, M | 1 |
| Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O | 1 |
| Church, C; DePriest, CB; Dillman, RO; Dobbs, TW; Ruben, RH; Schulof, R; Soori, G; Wiemann, MC | 1 |
| Bocangel, DB; Kokkinakis, DM; Moschel, RC; Pegg, AE; Schold, SC | 1 |
| Bosik, ME; Chang, SM; Fink, KL; Fulton, D; Kuhn, JG; Mehta, MP; Prados, MD; Robins, HI; Schold, SC; Spence, AM | 1 |
| Aversa, SM; Cetto, GL; Chiarion Sileni, V; Corti, L; Favaretto, AG; Medici, M; Monfardini, S; Nortilli, R; Paccagnella, A | 1 |
| Frenkel, EP; Han, Q; Hoffman, RM; Kokkinakis, DM; Schold, SC; Tan, Y; Wick, JB; Xu, M | 1 |
| Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW | 1 |
| Prados, M | 1 |
| Bardenheuer, W; Flasshove, M; Jansen, M; Moritz, T; Seeber, S; Sorg, UR | 1 |
| Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S | 1 |
| Ansén, S; Bischoff, S; Bohlen, H; Diehl, V; Dietlein, M; Re, D; Scheidhauer, K; Schicha, H; Tesch, H; Weihrauch, MR; Wolf, J | 1 |
| Dolan, ME; Long, L | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D | 1 |
| Atzpodien, J; Bröcker, EB; Fluck, M; Kamanabrou, D; Müller, I; Neuber, K; Neumann, C; Patzelt, T; Paul, E; Reitz, M; Rünger, TM; Schuler, G; von den Driesch, P | 1 |
| Brugnara, S; Chiarion-Sileni, V; Freschi, A; Guida, M; Labianca, R; Lo Re, G; Nanni, O; Nortilli, R; Ridolfi, R; Romanini, A; Vitali, P | 1 |
| Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F | 1 |
| Blank, A; Bobola, MS; Haroldson, PD; Huynh, MB; Kolstoe, DD; Schoeler, KD; Silber, JR | 1 |
| Bernstein, Z; Drumea, K; Haim, N; Sklar, Z; Stein, ME; Steiner, M; Tsalic, M | 1 |
| Li, Y; McClay, EF | 1 |
| Aleĭnikova, OV; Pochetukhin, KV; Strongin, IuS | 1 |
| Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE | 1 |
| Balduzzi, A; Barbarino, M; Biroccio, A; Gold, B; Graziani, G; Levati, L; Lombardi, ML; Portarena, I; Tentori, L; Vergati, M | 1 |
| Clemons, M; El Teraifi, H; Griffiths, A; Howell, A; Kelly, J; Margison, GP; Margison, JM; Morris, CQ; Ranson, M | 1 |
| Bonmassar, E; D'Atri, S; Falcinelli, S; Fuggetta, MP; Jiricny, J; Marra, G; Pagani, E; Pepponi, R | 1 |
| Dmitruk, A; Kozlowski, L; Ostrowska, K; Wojtukiewicz, MZ; Zacharski, LR | 1 |
| del Palacio, A; Garau, M; Molina, L; Relaño, MT | 1 |
| Ariza, A; Balaña, C; Ballester, R; Mendez, P; Ramirez, JL; Rosell, R; Roussos, Y; Sanchez, JJ; Sarries, C; Taron, M | 1 |
| Friedman, HS; Houghton, PJ; Keir, ST | 1 |
| Chiarion-Sileni, V; Corgna, E; Dalla Palma, M; De Salvo, GL; Del Bianco, P; Labianca, R; Lo Presti, G; Lo Re, G; Nortilli, R; Ridolfi, R; Romanini, A | 1 |
| Akimov, MA; Barchuk, AS; Gel'fond, ML; Gershanovich, ML | 1 |
| Ahmed, MM; Chendil, D; Kokkinakis, DM; Moschel, RC; Pegg, AE | 1 |
| Calvet, D; Delattre, JY; Janoray, P; Rojas-Marcos, I | 1 |
| Eisen, TG; Lens, MB | 1 |
| Chang, SM; Fine, HA; Fink, KL; Greenberg, HS; Hess, KR; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, MP; Nicholas, MK; Prados, MD; Robins, HI; Schold, SC; Yung, WK | 1 |
| Campbell, E; Drengler, RL; Eckardt, JR; Gerson, SL; Hammond, LA; Johnson, T; Kuhn, JG; Rowinsky, EK; Smith, L; Von Hoff, DD; Weiss, GR | 1 |
| Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK | 1 |
| Ashley, DL; Cher, L; Rosenthal, MA | 1 |
| Aguirre-Cruz, L; Crinière, E; Delattre, JY; Duprez, A; Golmard, JL; Kujas, M; Leuraud, P; Marie, Y; Medioni, J; Poupon, MF; Sanson, M; Taillandier, L | 1 |
| Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L | 1 |
| Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ | 1 |
| Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R | 1 |
| Chinnasamy, D; Chinnasamy, N; Fairbairn, LJ; Hanson, JP; Margison, GP; Neuenfeldt, J; Treisman, JS | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Feun, L; Hurley, J; Marini, A; Mazumder, A; Moffat, F; Savaraj, N | 1 |
| Cairncross, JG; Mymryk, JS; Xu, GW | 2 |
| Blank, A; Bobola, MS; Ellenbogen, RG; Geyer, JR; Goff, RD; Silber, JR | 1 |
| Cai, S; Cooper, RJ; Ferkowicz, MJ; Hartwell, JR; Kelley, MR; Pollok, KE; Xu, Y | 1 |
| Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC | 1 |
| Ashby, L; LaRocca, R; Ryken, T | 1 |
| Duncan, T; Lindahl, T; Paik, J; Sedgwick, B | 1 |
| Bredel, C; Bredel, M; Duran, GE; Harsh, GR; Juric, D; Recht, LD; Scheck, AC; Sikic, BI; Vogel, H; Yu, RX | 1 |
| Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J | 1 |
| Covas, DT; Davis, BM; Encell, LP; Fontes, AM; Gerson, SL; Lingas, K; Loeb, LA; Pegg, AE; Zago, MA | 1 |
| Reardon, DA | 1 |
| Audra, P; Cartalat-Carel, S; Colin, P; Ducray, F; Gaucherand, P; Honnorat, J; Mahla, K; Pelissou-Guyotat, I; Trouillas, P | 1 |
| Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A | 1 |
| Delaney, SM; Dolan, ME; Hansen, RJ; Nagasubramanian, R; Samson, LD | 1 |
| Chen, CC; D'Andrea, A; Taniguchi, T | 1 |
| Barcia, JA; Barcia-Mariño, C; Gallego, JM | 1 |
| Ducray, F; Honnorat, J | 1 |
| Brandes, AA; Franceschi, E; Tosoni, A | 1 |
| DeAngulo, G; Heimberger, AB; Hussain, SF; Jordan, JT; Prabhu, SS; Sun, W | 1 |
| Lau, TK; Li, RH; Mok, TS; Ng, PC; Tam, B; Tam, WH | 1 |
| Al-Ali, HK; Niederwieser, D; Wittekind, C | 1 |
| Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Price, A; Rogers, G; Somerville, M; Stein, K | 1 |
| Aoki, T; Hashimoto, N; Matsutani, M | 1 |
| Barada, WM; Bazarbachi, A; Beydoun, A; Hourani, R; Masroujeh, R; Otrock, ZK | 1 |
| Kleinberg, LR; Lin, SH | 1 |
| Mitchell, SB; Pan, E; Tsai, JS | 1 |
| Ogawa, M; Ueda, T; Yamauchi, T | 1 |
| Geisert, EE; Kang, GS; Kirichenko, OV; Miller, DD; Mohler, ML; Orr, WE; Patil, R; Wang, XD | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Adumala, RR; Altaha, R; Crowell, EB; Hobbs, GR; Vinjamuri, M | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Gathinji, M; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, AR; Than, K; Weingart, JD | 1 |
| Attenello, FJ; Brem, H; Chaichana, KL; Grossman, SA; Kleinberg, LR; Laterra, J; McGirt, MJ; Olivi, A; Quiñones-Hinojosa, A; Than, KD; Weingart, JD | 1 |
| Heymann, S; Karamanoukian, D; Noël, G; Quetin, P; Schott, R | 1 |
| Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K | 1 |
| Choi, U; Clevenger, JR; Donahue, RE; Dunbar, CE; Kang, E; Krouse, A; Larochelle, A; Loktionova, NA; Malech, HL; Metzger, M; Naumann, N; Persons, D; Shou, Y; Sorrentino, BP; Stewart, C | 1 |
| Affronti, ML; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Heery, CR; Herndon, JE; Reardon, DA; Rich, JN; Vredenburgh, JJ | 1 |
| Nishikawa, R | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Kuruvilla, J | 1 |
| Brandes, A; de Biase, D; Ermani, M; Franceschi, E; Marucci, G; Morandi, L; Pession, A; Tallini, G; Tosoni, A | 1 |
| Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A | 1 |
| Brem, H; McGirt, MJ | 1 |
| Cochran, BH; Daou, MC; Gilbert, CA; Li, L; Mihaliak, AM; Moser, RP; Reeves, A; Ross, AH | 1 |
| Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E | 1 |
| Emmerich, J; Giménez-Pando, J; Gómez-González, E; Márquez-Rivas, J; Ollero-Ortiz, A; Quiroga-Cantero, E; Ramirez, G; Rivas, E | 1 |
| Baumann, RP; Ishiguro, K; Penketh, PG; Sartorelli, AC; Shyam, K; Zhu, YL | 1 |
| Kim, JH; Kim, ST; Kim, WS; Kong, DS; Kwon, KH; Lee, JI; Lim, DH; Nam, DH; Park, K; Suh, YL | 1 |
| Bock, HC; Buchalla, R; Giese, A; Kantelhardt, SR; Ketter, R; Koll, S; Lohmann, F; Puchner, MJ; Rainov, N; Rohde, V; Schütze, M | 1 |
| Chen, C; Damek, DM; Franklin, W; Gaspar, LE; Kavanagh, BD; Kleinschmidt-DeMasters, BK; Lillehei, K; Olsen, C; Rusthoven, KE; Waziri, A | 1 |
| Bei, D; Meng, J; Youan, BB | 1 |
| Chansriwong, P; Sirisinha, T | 1 |
| Boyer, P; Dufour, P; Fischer-Lokou, D; Froelich, S; Gaub, MP; Kehrli, P; Maitrot, D; Noël, G; Schott, R | 1 |
| Achawal, S; Dixit, S; Hingorani, M; Scott, I | 1 |
| Stummer, W; van den Bent, MJ; Westphal, M | 1 |
| Dib, M; Gagnadoux, F; Paris, A; Rousselet, MC; Tazi, A; Urban, T | 1 |
| Casali, C; Di Meco, F; Duri, S; Gaviani, P; Milanesi, I; Salmaggi, A; Silvani, A | 1 |
| Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Bernaudin, M; Chapon, F; Colin, P; Diebold, MD; Dugué, AE; Emery, E; Guillamo, JS; Lechapt-Zalcman, E; Levallet, G; Menei, P; Peruzzy, P; Vital, A | 1 |
| Bouchekoua, M; Hieu, PD; Malhaire, JP; Miglierini, P; Pradier, O; Rousseau, B | 1 |
| Breneman, JC; Gerena-Lewis, M; McPherson, CM; Warnick, RE | 1 |
| Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P | 1 |
| Beard, BC; Gori, JL; Ironside, C; Karponi, G; Kiem, HP | 1 |
| Barr, JG; Grundy, PL | 1 |
| Anile, C; Balducci, M; Chiesa, S; De Bonis, P; Fiorentino, A; Maira, G; Mangiola, A; Pompucci, A | 1 |
| Balabanov, S; Bokemeyer, C; Braig, M; Hagel, C; Hauber, J; Lamszus, K; Pällmann, N; Preukschas, M; Schulte, A; Sievert, H; Weber, K | 1 |
| Allgayer, H; Fruehauf, S; Heckmann, D; Laufs, S; Maier, P; Spier, I; Wenz, F; Zeller, WJ; Zucknick, M | 1 |
| Payne, CA; Safdar, S; Taite, LJ; Tu, NH | 1 |
| Chen, G; Colman, H; Feng, L; Huang, P; Keating, MJ; Li, X; Wang, F; Wang, J; Wang, L; Xu, RH; Yuan, S; Zhang, H | 1 |
| Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E | 1 |
| Casali, C; Ciusani, E; Dimeco, F; Fariselli, L; Gaviani, P; Guzzetti, S; Maccagnano, C; Marchetti, M; Milanesi, I; Pollo, B; Salmaggi, A; Silvani, A; Solero, CL | 1 |
| Braunsdorf, WE; Giese, A; Gutenberg, A; Lumenta, CB; Mehdorn, HM; Sabel, M; Westphal, M | 1 |
| Aslan, D; Cetin, M; Eroglu, C; Eser, B; Kaynar, L; Keklik, M; Kurnaz, F; Mentes, S; Orhan, O; Sahin, C; Sivgin, S; Soyuer, S; Unal, A; Yildiz, OG | 1 |
| Bock, HC; Brück, W; Doerner, L; Felsberg, J; Giese, A; Gutenberg, A; Mehdorn, HM; Reifenberger, G; Roggendorf, W; Westphal, M | 1 |
| Antonietti, P; Balss, J; Capper, D; Frank, J; Kögel, D; Mohrenz, IV; Mukrowsky, A; Pusch, S; Seifert, V; Senft, C; Voigt, S; von Deimling, A; Weissert, S | 1 |
| Classen, CF; Krohn, M; Linnebacher, M; Mullins, CS; Schneider, B; Stockhammer, F | 1 |
| Chamberlain, MC | 1 |
| Ewelt, C; Hänggi, D; Isik, G; Sabel, M; Samis Zella, MA; Schroeteler, J; Slotty, PJ; Steiger, HJ; Wallocha, M | 1 |
| Bardin, AL; Carson-Walter, E; Cui, W; Folts, CJ; Noble, M; Stevens, BM; Vescovi, A; Walter, K | 1 |
| Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY | 1 |
| Daw, S; Hayward, J; Hewitt, M; Kirkwood, A; McCarthy, K; Morland, B; Shankar, A | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Beveridge, RD; Carroll, TA; Collis, SJ; Cox, A; Depondt, ML; Fernando, M; Jellinek, D; Kriplani, DH; Myers, KN; Patil, AA; Roylance, A; Sayal, P | 1 |
| Hay, JW; Messali, A; Villacorta, R | 1 |
| Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR | 1 |
| Bates, A; Cooke, R; Cunningham, D; Falk, SJ; Gilson, D; Hancock, BW; Harris, SJ; Horwich, A; Hoskin, PJ; Linch, DC; Lister, A; Lucraft, HH; Radford, J; Stevens, AM; Swerdlow, AJ; Syndikus, I; Williams, MV | 1 |
| Nagai, H | 1 |
| Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF | 1 |
| Barford, K; Braun, CJ; Cerniauskas, E; Chen, Y; Hemann, MT; Lees, JA; Mazzucato, P; McFaline-Figueroa, JL; Nagel, ZD; Samson, LD; Sangaraju, D; Stanciu, M; Tretyakova, N; Vargas, A; White, FM | 1 |
| Banković, J; Dinić, J; Hadžić, S; Isaković, A; Paunović, V; Pešić, M; Podolski-Renić, A; Stanković, T; Stojković, S; Tanić, N | 1 |
| Brem, H; Burger, P; Chaichana, KL; Gallia, GL; Grossman, R; Olivi, A; Quiñones-Hinojosa, A; Sidransky, D; Soudry, E; Tyler, B; Weingart, J; Ye, X | 1 |
| Chakrabarti, M; Ray, SK | 1 |
| Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ | 1 |
| Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X | 1 |
| Borkowska, P; Fila-Daniłow, A; Kowalczyk, M; Kowalski, J; Paul-Samojedny, M; Pudełko, A; Suchanek-Raif, R | 1 |
| Ashby, LS; Smith, KA; Stea, B | 1 |
| Hirose, Y; Ohba, S | 1 |
| Azzalin, A; Buffo, A; Garello, F; Magrassi, L; Nato, G; Parmigiani, E | 1 |
| Cappabianca, P; Cavallo, LM; Frio, F; Grujicic, D; Illic, R; Lavrnic, S; Milicevic, M; Milosevic, S; Nikitovic, M; Raicevic, S; Savic, D; Solari, D; Somma, T | 1 |
| Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A | 1 |
| Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J | 1 |
| Akiyama, Y; Enatsu, R; Kimura, Y; Mikami, T; Mikuni, N; Wanibuchi, M | 1 |
| Akhtar, S; Elhassan, TAM; Elshenawy, MA; Maghfoor, I; Shahzad Rauf, M | 1 |
32 review(s) available for dacarbazine and carmustine
| Article | Year |
|---|---|
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Mice; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Male; Mitomycins; Placebos; Rectal Neoplasms; Semustine | 1976 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; Humans; Lomustine; Medulloblastoma; Methotrexate; Nitrogen Mustard Compounds; Procarbazine; Semustine; Teniposide; Vincristine | 1975 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
[Treatment of relapses and failures in disseminated Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Epirubicin; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Mechlorethamine; Melphalan; Methotrexate; Mitoguazone; Prednisone; Procarbazine; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine | 1991 |
[Brain metastases of malignant melanomas].
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Interleukin-2; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Semustine | 1991 |
Chemical xenogenization of experimental tumors.
Topics: Animals; Antigens, Neoplasm; Carmustine; Cell Line; Dacarbazine; DNA; Histocompatibility Antigens; Immunotherapy; Methylation; Methylnitronitrosoguanidine; Neoplasms, Experimental; T-Lymphocytes, Cytotoxic; Triazenes | 1987 |
Unresolved issues in combination chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Carmustine; Cell Cycle; Cyclophosphamide; Dacarbazine; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Fluorouracil; Humans; Leukemia, Experimental; Metabolic Clearance Rate; Methotrexate; Neoplasm Transplantation | 1986 |
Malignant melanoma of the genitourinary tract.
Topics: Adrenal Gland Neoplasms; Adult; Aged; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Melanoma; Middle Aged; Penile Neoplasms; Prostatic Neoplasms; Radiotherapy Dosage; Testicular Neoplasms; Ureteral Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1984 |
Tamoxifen: is it useful in the treatment of patients with metastatic melanoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Synergism; Humans; Melanoma; Tamoxifen; Treatment Outcome | 1994 |
The Dartmouth Regimen: gone or going strong?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Tamoxifen | 1998 |
Future directions in the treatment of malignant gliomas with temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Resistance, Neoplasm; Genetic Therapy; Glioblastoma; Humans; Temozolomide; Topotecan | 2000 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
Systemic chemotherapy for the treatment of metastatic melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carmustine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Humans; Melanoma; Nitrosourea Compounds; Paclitaxel; Tamoxifen; Taxoids; Temozolomide | 2002 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Temozolomide | 2003 |
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Humans; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vincristine | 2003 |
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?].
Topics: Age Factors; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Survival Rate; Temozolomide; Tomography, X-Ray Computed | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioma; Humans; Male; Middle Aged; Models, Econometric; Neoplasm Staging; Quality of Life; Temozolomide | 2007 |
Management of glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Genetic Therapy; Glioblastoma; Humans; Immunotherapy; Polyesters; Temozolomide | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Delayed-Action Preparations; Glioma; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Temozolomide | 2008 |
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Glioblastoma; Humans; Leukemia, Myeloid, Acute; Lomustine; Myelodysplastic Syndromes; Neoplasms, Second Primary; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Standard therapy of advanced Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Mechlorethamine; Melphalan; Methylprednisolone; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vincristine; Vindesine | 2009 |
Engineering nanomedicines for improved melanoma therapy: progress and promises.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Dacarbazine; Drug Delivery Systems; Humans; Melanoma; Nanomedicine; Tamoxifen | 2010 |
The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Drug Implants; Glioblastoma; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Polyesters; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Temozolomide; Venous Thromboembolism; Young Adult | 2011 |
Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide; Treatment Outcome | 2011 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Prognosis; Temozolomide | 2013 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Disease Progression; Evidence-Based Medicine; Glioblastoma; Humans; Temozolomide | 2014 |
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
Topics: Antineoplastic Agents; Carmustine; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Dacarbazine; Disease-Free Survival; Glioblastoma; Health Care Costs; Humans; Quality-Adjusted Life Years; Temozolomide | 2014 |
[Treatment strategy of Hodgkin lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunoconjugates; Mechlorethamine; Melphalan; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Rituximab; Vinblastine; Vincristine | 2014 |
Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Drug Implants; Glioblastoma; Humans; Middle Aged; Neoplasm Grading; Polyesters; Temozolomide; United States; United States Food and Drug Administration | 2016 |
Current and Future Drug Treatments for Glioblastomas.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Immunotherapy; Temozolomide | 2016 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Dosage Forms; Glioma; Humans; Neoplasm Recurrence, Local; Neurosurgical Procedures; Quality of Life; Randomized Controlled Trials as Topic; Temozolomide | 2017 |
79 trial(s) available for dacarbazine and carmustine
| Article | Year |
|---|---|
Malignant melanoma (stage IIIB): a pilot study of adjuvant chemo-immunotherapy.
Topics: Adult; Aged; Antigens, Neoplasm; BCG Vaccine; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Pilot Projects | 1978 |
Chemotherapy of large intestinal carcinoma. Current results and future prospects.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Intravenous; Rectal Neoplasms; Semustine; Vincristine | 1975 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Lomustine; Melanoma; Mice; Neoplasm Metastasis; Nitrosourea Compounds; Remission, Spontaneous; Triazenes | 1976 |
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; Nausea; Sex Factors; Thrombocytopenia; Triazenes; Vincristine; Vomiting | 1976 |
DTIC (NSC-45388) studies in the southwest oncology group.
Topics: Carmustine; Chlorpromazine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Hodgkin Disease; Humans; Leukopenia; Lymphoma; Melanoma; Nausea; Neoplasm Metastasis; Remission, Spontaneous; Thrombocytopenia; Triazenes; Vincristine; Vomiting | 1976 |
Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lomustine; Male; Melanoma; Middle Aged; Sex Factors; Skin Neoplasms; Triazenes | 1976 |
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasms; Neuroblastoma; Rhabdomyosarcoma; Triazenes; Vincristine | 1976 |
A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Stomach Neoplasms; Time Factors; Vincristine | 1976 |
Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
Topics: Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Pennsylvania; Prospective Studies; Triazenes; Vincristine | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Male; Mitomycins; Placebos; Rectal Neoplasms; Semustine | 1976 |
DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Middle Aged; Triazenes; United States; Vincristine | 1976 |
Comparative evaluation of three combination regimens for advanced malignant melanoma: results of an international cooperative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Central Nervous System Diseases; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Vincristine | 1976 |
A prospective randomized study of two alternating, non cross-resistant chemotherapies for advanced Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mitoguazone; Prednisone; Procarbazine; Prospective Studies; Survival Rate; Vinblastine; Vincristine | 1992 |
Chemotherapy for advanced malignant melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Humans; Immunologic Factors; Incidence; Interferon-alpha; Melanoma; Pilot Projects; Skin Neoplasms; Tamoxifen; Transplantation, Autologous | 1992 |
Sequential chemoimmunotherapy in the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1992 |
Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Procarbazine | 1986 |
Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis | 1987 |
[Adjuvant chemotherapy in addition to radical surgical treatment of regional lymph node metastases in malignant melanoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Inguinal Canal; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Melanoma; Neoplasm Staging; Prognosis | 1986 |
Management of Kaposi's sarcoma. Chemotherapy II.
Topics: Bleomycin; Carmustine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Humans; Razoxane; Sarcoma, Kaposi; Uganda; Vincristine | 1981 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Male; Middle Aged; Prednisone; Probability; Prognosis; Radiotherapy Dosage; Random Allocation; Semustine | 1983 |
Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Dactinomycin; Humans; Hydroxyurea; Levamisole; Melanoma; Random Allocation; Skin Neoplasms | 1984 |
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; Dacarbazine; Female; Humans; Hydroxyurea; Lomustine; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sex Factors; Skin Neoplasms; Soft Tissue Neoplasms; Time Factors; Vincristine | 1984 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea (FIVB) in colon cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Fluorouracil; Humans; Vincristine | 1981 |
Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon Type I; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1995 |
High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leucovorin; Male; Mechlorethamine; Methotrexate; Prednisolone; Prednisone; Procarbazine; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 1995 |
Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infusions, Intravenous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1995 |
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Hypotension; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Transplantation, Autologous | 1994 |
Sequential therapy with dacarbazine and carmustine: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Methyltransferases; Middle Aged; Monocytes; Neoplasms; Neutropenia; O(6)-Methylguanine-DNA Methyltransferase; Thrombocytopenia | 1994 |
Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cachexia; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Drug Tolerance; Female; Humans; Male; Megestrol; Megestrol Acetate; Melanoma; Middle Aged; Remission Induction; Survival Rate; Time Factors | 1994 |
Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Soft Tissue Neoplasms; Tamoxifen | 1993 |
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Sex Characteristics; Survival Rate; Tamoxifen | 1995 |
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Tamoxifen | 1996 |
Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Prognosis; Singapore; Skin Neoplasms; Survival Rate; Tamoxifen | 1996 |
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Skin Neoplasms; Tamoxifen; Treatment Outcome | 1997 |
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Confidence Intervals; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Humans; Interferon alpha-2; Interferon-alpha; Melanoma; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Tamoxifen | 1997 |
Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; L-Lactate Dehydrogenase; Male; Melanoma; Middle Aged; Prognosis; Recombinant Proteins; Survival Rate; Tamoxifen; Treatment Outcome | 1997 |
Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen | 1998 |
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Flow Cytometry; Humans; Interferon-alpha; Interleukin-2; Killer Cells, Natural; Lymphocyte Activation; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; T-Lymphocytes; Tamoxifen; Treatment Outcome | 1998 |
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Prognosis; Risk; Survival Analysis; Tamoxifen; Treatment Outcome | 1998 |
Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Glutathione; Humans; Male; Melanoma; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin | 1996 |
Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon-alpha; Lung Neoplasms; Male; Melanoma; Middle Aged; Prospective Studies; Remission Induction; Skin Neoplasms; Tamoxifen | 1999 |
Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Pilot Projects; Recombinant Proteins; Treatment Outcome | 1999 |
Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Eye Neoplasms; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen; Treatment Outcome | 1999 |
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 1999 |
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease Progression; Female; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Tamoxifen | 2000 |
A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cisplatin; Dacarbazine; Dendritic Cells; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Macrophages; Male; Melanoma; Middle Aged; Recombinant Proteins; Survival Analysis; Time Factors | 1998 |
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Survival Rate; Tamoxifen | 2000 |
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Half-Life; Humans; Maximum Tolerated Dose; Temozolomide | 2000 |
Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Tamoxifen; Time Factors; Treatment Outcome | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Implants; Drug Synergism; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Safety; Supratentorial Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome | 2001 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Male; Melanoma; Middle Aged; Procarbazine; Skin Neoplasms; Time Factors; Treatment Outcome; Vincristine | 2002 |
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2002 |
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Male; Melanoma; Middle Aged; Outpatients; Proportional Hazards Models; Prospective Studies; Quality of Life; Recombinant Proteins; Skin Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2002 |
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma; Middle Aged; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Analysis; Tamoxifen | 2002 |
Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Dacarbazine; Enoxaparin; Feasibility Studies; Glycosaminoglycans; Humans; Melanoma; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Multivariate Analysis; Prognosis; Quality of Life; Recombinant Proteins; Skin Neoplasms | 2003 |
[Chemotherapy in combination with laser coagulation or interstitial hyperthermia--effective combined therapy for disseminated skin melanoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Extracellular Space; Female; Humans; Hyperthermia, Induced; Laser Coagulation; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Tamoxifen; Treatment Outcome | 2003 |
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Confidence Intervals; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; North America; Temozolomide | 2004 |
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neutrophils; Temozolomide | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Female; Glioma; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Survival Analysis; Temozolomide | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Female; Humans; Male; Middle Aged; Pilot Projects; Temozolomide | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Radiotherapy; Temozolomide | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Cyclosporine A, alpha-lnterferon and interleukin-2 following chemotherapy with BCNU, DTIC, cisplatin, and tamoxifen: a phase II study in advanced melanoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclosporine; Dacarbazine; Female; Humans; Immunosuppressive Agents; Interferon-alpha; Interleukin-2; Male; Melanoma; Skin Neoplasms; Tamoxifen; Treatment Outcome | 2005 |
Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Treatment Outcome | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Impact of adjuvant chemotherapy for gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Child; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; Humans; Lomustine; Male; Middle Aged; Neoplasm Staging; Neoplasms, Neuroepithelial; Neoplasms, Radiation-Induced; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Vincristine; Young Adult | 2010 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Grading; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Temozolomide | 2012 |
Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Female; Glioblastoma; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Prospective Studies; Temozolomide | 2012 |
Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Therapy, Combination; Female; Follow-Up Studies; Glioblastoma; Humans; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Neurosurgical Procedures; Prospective Studies; Radiotherapy; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2013 |
MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Temozolomide | 2013 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Female; Genetic Therapy; Glioblastoma; Guanine; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Models, Biological; Prospective Studies; Temozolomide; Tumor Suppressor Proteins | 2014 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Postoperative Period; Prognosis; Prospective Studies; Radiotherapy Dosage; Survival Rate; Temozolomide | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmustine; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Electric Stimulation Therapy; Europe; Female; Glioblastoma; Humans; Israel; Maintenance Chemotherapy; Male; Middle Aged; Republic of Korea; Temozolomide; United States; Young Adult | 2015 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazine; Female; Follow-Up Studies; Humans; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Procarbazine; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Vincristine | 2016 |
183 other study(ies) available for dacarbazine and carmustine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carmustine; Dacarbazine; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Female; Humans; Male; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms, Experimental | 1979 |
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Dacarbazine; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Graft Rejection; Guinea Pigs; Injections; Injections, Intraperitoneal; Liver Neoplasms; Melphalan; Mercaptopurine; Methotrexate; Mitomycins; Neoplasm Transplantation; Neoplasms, Experimental | 1976 |
Direct delivery of anticancer agents: experimental treatment of intraocular malignancy.
Topics: Animals; Anterior Chamber; Carcinoma, Brown-Pearce; Carmustine; Conjunctiva; Dacarbazine; Eye Neoplasms; Female; Injections; Injections, Intravenous; Rabbits; Triazenes | 1978 |
Interrelationship between chemotherapy and immunotherapy in the treatment of disseminated disease.
Topics: Animals; Carmustine; Dacarbazine; Humans; Immunity; Immunotherapy; Leukemia L1210; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasms | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neoplasms; Cyclophosphamide; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Mitolactol; Neoplasms; Osteosarcoma; Pancreatic Neoplasms; Rectal Neoplasms; Vincristine | 1976 |
Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma.
Topics: Carmustine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Neoplasm Metastasis; Remission, Spontaneous; Triazenes; Vincristine | 1977 |
Combination chemotherapy of malignant melanoma with imidazole carboxamide, BCNU and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Triazenes; Vincristine | 1977 |
Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma.
Topics: Carmustine; Chlorpromazine; Dacarbazine; Drug Therapy, Combination; Eosinophils; Female; Humans; Leukocyte Count; Lymphocytes; Male; Melanoma; Monocytes; Neoplasm Metastasis; Remission, Spontaneous; Time Factors; Triazenes; Vincristine | 1977 |
Immunogenicity induced in vivo by DIC in relatively non-immunogenic leukemias.
Topics: Animals; Antibody Formation; Carmustine; Dacarbazine; Leukemia; Leukemia, Experimental; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Neoplasm Transplantation; Radiation Effects; Transplantation, Isogeneic; Triazenes | 1977 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomustine; Melanoma; Neoplasm Metastasis; Skin Neoplasms; Vincristine | 1977 |
5-Fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Rectal Neoplasms; Remission, Spontaneous; Vincristine | 1976 |
[Results with new cytotoxic agents].
Topics: Carmustine; Dacarbazine; Gastrointestinal Neoplasms; Humans; Melanoma; Remission, Spontaneous; Triazenes | 1976 |
Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Humans; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Triazenes; Vincristine | 1976 |
[Models of polychemotherapy in acute leukemias].
Topics: Acute Disease; Antineoplastic Agents; Asparaginase; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Drug Therapy, Combination; Humans; Leukemia; Mercaptopurine; Thioguanine | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Procarbazine; Remission, Spontaneous; Skin Neoplasms; Triazenes; Vincristine | 1975 |
Chemotherapy of melanoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Nitrosourea Compounds; Semustine; Skin Neoplasms; Vinca Alkaloids | 1975 |
Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
Topics: Animals; Antigens, Neoplasm; Carmustine; Cell Line; Cross Reactions; Cyclophosphamide; Dacarbazine; Immunotherapy; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Moloney murine leukemia virus; Neoplasm Transplantation; Radiation Effects; Rauscher Virus; Transplantation, Isogeneic; Triazenes | 1976 |
[Treatment of metastasising melanoma with a combination of cytostatic agents (author's transl)].
Topics: Adult; Bone Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Skin Neoplasms; Soft Tissue Neoplasms; Triazenes; Vincristine | 1976 |
Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Lymph Node Excision; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Skin Neoplasms; Survival Rate; Tamoxifen | 1992 |
Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Florida; Follow-Up Studies; Hospitals, University; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Survival Rate; Tamoxifen | 1992 |
New approaches to the chemotherapy of melanoma.
Topics: Alkaloids; Amifostine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Daunorubicin; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Paclitaxel; Procarbazine; Tamoxifen; Taurine; Thiotepa; Vincristine; Vindesine | 1991 |
Malignant melanoma: primary presentation in bone marrow and lymph node.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Cisplatin; Dacarbazine; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Tamoxifen | 1992 |
Effective chemotherapy for melanoma after treatment with interleukin-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Remission Induction; Tamoxifen | 1992 |
Role of levamisole as immunomodulant in mouse lymphoma model.
Topics: Animals; Carmustine; Cytarabine; Dacarbazine; Drug Synergism; Female; Immune Tolerance; Levamisole; Lymphoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Transplantation, Homologous | 1991 |
Sequential chemoimmunotherapy for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Tamoxifen; Thrombocytopenia | 1991 |
In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Topics: Antineoplastic Agents; Carmustine; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Lomustine; Melanoma; Nitrosourea Compounds; Organophosphorus Compounds; Thymidine; Tumor Cells, Cultured | 1990 |
DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives.
Topics: Animals; Azacitidine; Carmustine; Cell Line; Cytarabine; Dacarbazine; DNA, Neoplasm; Lymphoma; Male; Methylation; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Quinacrine; Triazenes | 1987 |
Allogeneic marrow transplantation for refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Prednisone; Procarbazine; Remission Induction; Vinblastine; Vincristine | 1989 |
Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.
Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esterases; Female; Flow Cytometry; Mammary Neoplasms, Experimental; Mesylates; Mice; Nitrogen Mustard Compounds; Spectrometry, Fluorescence; Temozolomide; Thiepins; Tumor Cells, Cultured | 1989 |
Combined modality therapy for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Resistance; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mediastinal Neoplasms; Middle Aged; Prednisone; Procarbazine; Prognosis; Vinblastine; Vincristine | 1985 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Female; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Prednisone; Retrospective Studies; Time Factors; Vincristine | 1989 |
The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombophlebitis | 1989 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Benzoquinones; Carmustine; Cerebellar Neoplasms; Child; Dacarbazine; Drug Evaluation; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics as Topic | 1987 |
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazine; Humans; Hydroxyurea; Lymph Node Excision; Lymphatic Metastasis; Melanoma; Neoplasm Recurrence, Local; Postoperative Care; Skin Neoplasms; Time Factors | 1987 |
Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Kidney Diseases; Leukopenia; Male; Melanoma; Middle Aged; Nausea; Pulmonary Embolism; Skin Neoplasms; Tamoxifen; Thrombocytopenia; Thromboembolism; Vomiting | 1987 |
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.
Topics: Animals; Antineoplastic Agents; Carmustine; Dacarbazine; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resistance; Flow Cytometry; Leukemia L1210; Methylation; Methyltransferases; Mice; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 1987 |
Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dactinomycin; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Vincristine | 1986 |
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Female; Humans; Interferon Type I; Lomustine; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Recombinant Proteins; Skin Neoplasms; Vincristine | 1987 |
Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Dacarbazine; Female; Humans; Male; Melanoma; Neoplasm Metastasis; Vincristine | 1983 |
Intrahepatic chemotherapy in isolated liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Prognosis; Vincristine | 1983 |
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Cyclophosphamide; Dacarbazine; Drug Resistance; Female; Lymphoma, Large B-Cell, Diffuse; Melphalan; Mice; Mice, Inbred C57BL; Ovarian Neoplasms | 1983 |
Increased immunogenicity of murine lymphoma cells following exposure to gamma rays in vivo.
Topics: Animals; Carmustine; Dacarbazine; Gamma Rays; Histocompatibility Antigens; Immune Tolerance; Immunity; Leukemia L1210; Lymphoma; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation | 1984 |
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Tamoxifen | 1984 |
[Marked regression of melanoma metastases under combined chemotherapy].
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Female; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Middle Aged; Skin Neoplasms | 1984 |
Combination chemotherapy with AMSA on L1210 leukaemia and B16 melanoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Leukemia L1210; Male; Melanoma; Melphalan; Mice; Mice, Inbred Strains; Neoplasms, Experimental | 1981 |
Chemotherapy and immunotherapy of L1210 leukemic mice with antigenic tumor sublines.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carmustine; Cell Line; Cyclophosphamide; Dacarbazine; Immunologic Techniques; Immunotherapy; Leukemia L1210; Mice; T-Lymphocytes | 1981 |
In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3,3'-dimethyl-1-triazeno)imidazole-4-carboxamide.
Topics: Animals; Antigens, Neoplasm; Carmustine; Cell Line; Cytological Techniques; Dacarbazine; Leukemia L1210; Mice; Mice, Inbred C57BL; Microsomes, Liver; Neoplasm Transplantation; Prognosis; Transplantation Immunology | 1981 |
Management of drug toxicities and infections.
Topics: Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Humans; Infections; Methotrexate; Neoplasms | 1980 |
A five-drug combination in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis; Prednisone | 1981 |
Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy.
Topics: Adult; Carmustine; Dacarbazine; Eye Neoplasms; Female; Humans; Lomustine; Melanoma; Retina; Skin Neoplasms; Vitreous Body | 1981 |
Combined effects of antineoplastic agents and anti-lymphoma allograft reactions.
Topics: Animals; Antineoplastic Agents; Carmustine; Cyclophosphamide; Dacarbazine; Female; Histocompatibility; Host vs Graft Reaction; Leukemia L1210; Leukemia, Experimental; Lymphoma; Male; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Transplantation, Homologous; Vincristine | 1980 |
Chemotherapy against human melanoma in the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cheek; Cricetinae; Cyclophosphamide; Dacarbazine; Doxorubicin; Fluorouracil; Humans; Male; Melanoma; Methotrexate; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Vincristine | 1980 |
Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Topics: Antineoplastic Agents; Bleomycin; Carboplatin; Carmustine; Cisplatin; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fluorouracil; Forecasting; Humans; In Vitro Techniques; Lymphatic Metastasis; Melanoma; Methotrexate; Nitrosourea Compounds; Organophosphorus Compounds; Pilot Projects; Remission Induction; Retrospective Studies; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1994 |
Activity of temozolomide in the treatment of central nervous system tumor xenografts.
Topics: Animals; Carmustine; Central Nervous System Neoplasms; Dacarbazine; Female; Guanine; Humans; Male; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Procarbazine; Temozolomide; Transplantation, Heterologous | 1995 |
Combination chemotherapy of metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Tamoxifen | 1995 |
Mouse subrenal capsule assay chemosensitivity and DNA flow cytometry parameters of human melanoma metastases.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; DNA, Neoplasm; Etoposide; Female; Flow Cytometry; Humans; Male; Melanoma; Mice; Middle Aged; Subrenal Capsule Assay; Vincristine | 1994 |
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Dacarbazine; Humans; Methyltransferases; Mice; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1994 |
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Topics: Adult; Aged; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antineoplastic Combined Chemotherapy Protocols; Antiphospholipid Syndrome; Autoantibodies; Cardiolipins; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Dacarbazine; Female; Humans; Immunoglobulin G; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Male; Melanoma; Middle Aged; Recombinant Proteins; Tamoxifen; Thromboembolism | 1994 |
The chemohormonal therapy of metastatic melanoma: possible benefit of tamoxifen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Tamoxifen; Thrombophlebitis | 1993 |
Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Dacarbazine; Humans; Methyltransferases; Mice; Mice, Nude; Neoplasm Transplantation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1993 |
Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; Guanine; Humans; Methyltransferases; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Tumor Cells, Cultured | 1996 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Dacarbazine; Glioblastoma; Guanine; Humans; Kinetics; Methyltransferases; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1996 |
Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents.
Topics: 3T3 Cells; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Dacarbazine; Drug Resistance; Gene Transfer Techniques; Genetic Vectors; Hematopoietic Stem Cells; Humans; Methyltransferases; Mice; Moloney murine leukemia virus; O(6)-Methylguanine-DNA Methyltransferase | 1996 |
3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
Topics: Antineoplastic Agents, Alkylating; Benzamides; Carmustine; Dacarbazine; DNA Repair; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Guanine; Humans; Neoplasms; Temozolomide; Tumor Cells, Cultured | 1996 |
Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; DNA Adducts; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Enzyme Inhibitors; Guanine; Humans; Methylation; Methyltransferases; Microsatellite Repeats; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Carmustine; Cell Division; Dacarbazine; Drug Synergism; Female; Guanine; Hematopoietic Stem Cells; Male; Mice; Temozolomide | 1997 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, Antisense; Endothelial Growth Factors; Genetic Vectors; Glioma; Humans; Lymphokines; Male; Neoplasm Proteins; Neovascularization, Pathologic; Rats; Rats, Nude; Temozolomide; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1998 |
Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Combinations; Drug Resistance, Neoplasm; Guanine; Hematopoietic Stem Cells; Humans; Male; Mice; Mice, Inbred C3H; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic; Transfection; Tumor Cells, Cultured | 1999 |
DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinogens; Carmustine; Dacarbazine; Genotype; Hematopoietic System; Liver; Methylnitronitrosoguanidine; Mice; Mice, Knockout; Mitomycin; Models, Biological; O(6)-Methylguanine-DNA Methyltransferase; Streptozocin; Temozolomide | 1999 |
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Colonic Neoplasms; Dacarbazine; DNA Repair; Drug Synergism; Humans; Hydroxylamines; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide | 1999 |
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Idarubicin; Ifosfamide; Immunization, Passive; Interleukin-2; Male; Melphalan; Middle Aged; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Vinblastine; Vincristine | 1999 |
Human mesenchymal stem cells provide stromal support for efficient CD34+ transduction.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Cytokines; Dacarbazine; Drug Resistance, Multiple; Genetic Vectors; Hematopoiesis; Hematopoietic Stem Cells; Humans; Mesoderm; Monocytes; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Retroviridae; Signal Transduction; Stem Cells; Stromal Cells; Temozolomide | 1999 |
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dacarbazine; Humans; Melanoma; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
What can we learn from phase II adjuvant trials in melanoma?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Dacarbazine; Drug Synergism; Humans; Immunologic Factors; Interferons; Interleukin-2; Melanoma; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Research Design; Skin Neoplasms; Tamoxifen; Treatment Outcome; Vinblastine | 2000 |
Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; CHO Cells; Cricetinae; Cyclophosphamide; Dacarbazine; Drug Interactions; Enzyme Inhibitors; Guanine; Mutagenicity Tests; Mutagens; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Middle Aged; Podophyllotoxin; Prednisone; Procarbazine; Recurrence; Retrospective Studies; Survival Rate; Time Factors; Vinblastine; Vincristine | 2000 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carmustine; Dacarbazine; Deoxyguanosine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glioma; Guanine; Humans; Mice; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbon-Sulfur Lyases; Carmustine; Choline; Dacarbazine; Diet; Down-Regulation; Drug Synergism; Glioblastoma; Humans; Methionine; Mice; Mice, Inbred BALB C; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Proteins; Temozolomide; Xenograft Model Antitumor Assays | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dacarbazine; DNA-Binding Proteins; Dose-Response Relationship, Drug; E2F Transcription Factors; E2F1 Transcription Factor; Gene Transfer Techniques; Glioma; Humans; Inhibitory Concentration 50; Sensitivity and Specificity; Temozolomide; Transcription Factors; Tumor Cells, Cultured | 2001 |
Protection of hematopoietic cells from O(6)-alkylation damage by O(6)-methylguanine DNA methyltransferase gene transfer: studies with different O(6)-alkylating agents and retroviral backbones.
Topics: Alkylating Agents; Alkylation; Animals; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Dacarbazine; DNA Damage; DNA, Complementary; Drug Resistance; Genetic Vectors; Hematopoietic Stem Cells; Humans; Lomustine; Mice; Moloney murine leukemia virus; Nimustine; O(6)-Methylguanine-DNA Methyltransferase; Recombinant Fusion Proteins; Retroviridae; Sarcoma Viruses, Murine; Spleen Focus-Forming Viruses; Temozolomide; Terminal Repeat Sequences; Transfection | 2001 |
Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Diagnosis, Differential; Disease-Free Survival; Doxorubicin; Etoposide; False Negative Reactions; False Positive Reactions; Fibrosis; Fluorodeoxyglucose F18; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Life Tables; Mediastinal Neoplasms; Melphalan; Neoplasm Recurrence, Local; Predictive Value of Tests; Prednisone; Procarbazine; Prospective Studies; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Tomography, Emission-Computed; Transplantation, Autologous; Vinblastine; Vincristine | 2001 |
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
Topics: Antineoplastic Agents; Biotransformation; Carmustine; Cytochrome P-450 Enzyme System; Cytosol; Dacarbazine; DNA Repair; Guanine; Humans; Isoenzymes; Kinetics; Liver; Microsomes, Liver; Temozolomide | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosomes, Human, Pair 1; Combined Modality Therapy; Dacarbazine; DNA Fingerprinting; DNA, Neoplasm; Glioma; Glutathione Transferase; Humans; Immunohistochemistry; Intermediate Filament Proteins; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms, Experimental; Nerve Tissue Proteins; Nestin; Nitrosourea Compounds; Nucleic Acid Hybridization; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Survival Analysis; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vimentin; Xenograft Model Antitumor Assays | 2002 |
The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Apurinic Acid; Brain Neoplasms; Carbon-Oxygen Lyases; Carmustine; Dacarbazine; DNA Adducts; DNA Damage; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Induction; Glioblastoma; Humans; Hypochlorous Acid; Methyl Methanesulfonate; Neoplasm Proteins; O(6)-Methylguanine-DNA Methyltransferase; Oxidative Stress; Reactive Oxygen Species; Temozolomide; Tumor Cells, Cultured | 2002 |
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
Topics: Adolescent; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carboplatin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Data Interpretation, Statistical; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Rhabdomyosarcoma; Sarcoma, Ewing; Sex Factors; Statistics, Nonparametric; Time Factors; Transplantation, Autologous; Vinblastine | 2002 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide | 2002 |
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dacarbazine; DNA Ligases; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Melanoma; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Sulfones; Telomerase; Temozolomide; Transfection; Tumor Cells, Cultured | 2003 |
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy, Needle; Breast Neoplasms; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Immunoenzyme Techniques; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase | 2003 |
The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin.
Topics: Alkyl and Aryl Transferases; Base Pair Mismatch; Carmustine; Cisplatin; Clone Cells; Dacarbazine; DNA Ligases; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Melanoma; Temozolomide; Tumor Cells, Cultured | 2003 |
[Foliculitis in a patient with Hodkins disease].
Topics: Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Therapy; Cytarabine; Dacarbazine; Dermatomycoses; Dexamethasone; Doxorubicin; Etoposide; Folliculitis; Hodgkin Disease; Humans; Itraconazole; Malassezia; Male; Melphalan; Opportunistic Infections; Vinblastine | 2003 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; CpG Islands; Dacarbazine; Disease Progression; DNA; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors | 2003 |
Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; Deoxyguanosine; DNA Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Guanine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; O(6)-Methylguanine-DNA Methyltransferase; Pancreatic Neoplasms; Temozolomide; Time Factors | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Carboplatin; Carmustine; Dacarbazine; Disease Progression; Dose Fractionation, Radiation; Ependymoma; Gadolinium; Headache; Humans; Isotretinoin; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Remission Induction; Tamoxifen; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarbazine; Glioblastoma; Humans; Ifosfamide; Loss of Heterozygosity; Mice; Mice, Nude; Mutation; Oligodendroglioma; Temozolomide; Xenograft Model Antitumor Assays | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Methylation; DNA Repair; Female; Glioma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide; Treatment Outcome | 2004 |
Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide.
Topics: Antigens, CD34; Blotting, Western; Carmustine; Cell Line; Colony-Forming Units Assay; Dacarbazine; DNA Primers; Flow Cytometry; Gene Expression Regulation, Enzymologic; Genetic Therapy; Genetic Vectors; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lentivirus; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Temozolomide; Transduction, Genetic; Transgenes; Tumor Cells, Cultured | 2004 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Damage; Drug Interactions; Glioma; Humans; Temozolomide; Thiazoles; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain; Carmustine; Cell Survival; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Guanine; Humans; Male; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Time Factors; Tumor Cells, Cultured | 2005 |
Mitochondrial targeting of human O6-methylguanine DNA methyltransferase protects against cell killing by chemotherapeutic alkylating agents.
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Nucleus; Dacarbazine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Guanine; Hematopoietic Stem Cells; Humans; K562 Cells; Methyl Methanesulfonate; Mitochondria; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Middle Aged; Survival Analysis; Temozolomide | 2005 |
Treatment of brain tumors.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Glioblastoma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Survival Analysis; Temozolomide | 2005 |
Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.
Topics: Antineoplastic Agents; Astrocytoma; Blotting, Western; Carmustine; Cell Cycle; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Dacarbazine; Gene Silencing; Humans; Temozolomide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2005 |
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Genetic Vectors; HeLa Cells; Humans; Methyl Methanesulfonate; Ovarian Neoplasms; RNA Interference; RNA, Small Interfering; Temozolomide; Ultraviolet Rays; Uterine Cervical Neoplasms | 2005 |
Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Dosage; Gene Expression Profiling; Glioblastoma; Humans; Hyaluronan Receptors; Intracellular Signaling Peptides and Proteins; NF-kappa B; Nuclear Proteins; Proteins; Temozolomide; Tumor Necrosis Factor alpha-Induced Protein 3 | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Survival; Dacarbazine; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioma; Humans; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2006 |
Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells.
Topics: Alkylating Agents; Carmustine; Dacarbazine; Drug Resistance; Genetic Engineering; Guanine; Hematopoietic Stem Cells; Humans; K562 Cells; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transduction, Genetic | 2006 |
Glioblastoma--more questions than answers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carmustine; Central Nervous System Neoplasms; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Signal Transduction; Temozolomide | 2006 |
[Management of malignant gliomas diagnosed during pregnancy].
Topics: Abortion, Therapeutic; Adrenal Cortex Hormones; Adult; Algorithms; Anesthesia, General; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbamazepine; Carmustine; Case Management; Cesarean Section; Chemotherapy, Adjuvant; Cranial Irradiation; Craniotomy; Dacarbazine; Female; Frontal Lobe; Glioblastoma; Humans; Infant, Newborn; Intracranial Hypertension; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Paresis; Prednisolone; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Radiotherapy, Adjuvant; Remission Induction; Supratentorial Neoplasms; Temozolomide; Temporal Lobe | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioma; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Irinotecan; Paclitaxel; Structure-Activity Relationship; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vincristine | 2006 |
Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.
Topics: Alkylating Agents; Animals; Carmustine; Cell Line, Tumor; Cyclophosphamide; Dacarbazine; Guanine; Male; Mice; Mice, Transgenic; Mutagenicity Tests; Mutation; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Transfection | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; DNA Modification Methylases; DNA Repair; DNA Repair Enzymes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fanconi Anemia Complementation Group D2 Protein; Fanconi Anemia Complementation Group F Protein; Fanconi Anemia Complementation Group Proteins; Glioma; Guanine; Humans; Protein Processing, Post-Translational; RNA Interference; RNA, Small Interfering; Temozolomide; Time Factors; Transfection; Tumor Suppressor Proteins; Ubiquitins | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Drug Implants; Fatal Outcome; Female; Glioblastoma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Reoperation; Temozolomide; Temporal Lobe; Ventriculostomy | 2007 |
Adjuvant therapy in glioblastomas: false steps and real advances.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dacarbazine; Decanoic Acids; Glioblastoma; Humans; Polyesters; Temozolomide | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL22; Chemokines; Chemotaxis, Leukocyte; Cytoplasm; Dacarbazine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glioma; Humans; Receptors, CCR2; Receptors, CCR4; T-Lymphocytes, Regulatory; Temozolomide | 2008 |
Microphthalmos associated with Dartmouth combination chemotherapy in pregnancy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Dacarbazine; Female; Humans; Infant, Newborn; Liver Neoplasms; Male; Melanoma; Microphthalmos; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Pregnancy Trimester, Second; Skin Neoplasms; Tamoxifen | 2007 |
[Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Lymph Nodes; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Remission Induction; Rituximab; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells.
Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Confusion; Cryoprotective Agents; Cytarabine; Dacarbazine; Dexamethasone; Dimethyl Sulfoxide; Doxorubicin; Etoposide; Hippocampus; Hodgkin Disease; Humans; Hyperventilation; Ifosfamide; Magnetic Resonance Imaging; Male; Melphalan; Paresthesia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Vinblastine; Vision Disorders | 2008 |
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Drug Implants; Glioblastoma; Humans; Kaplan-Meier Estimate; Radiotherapy; Retrospective Studies; Temozolomide | 2008 |
Carmustine-resistant cancer cells are sensitized to temozolomide as a result of enhanced mismatch repair during the development of carmustine resistance.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadmium Chloride; Carmustine; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dacarbazine; DNA Mismatch Repair; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Guanine; Humans; Hydroxylamines; Nimustine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Temozolomide | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Evaluation, Preclinical; Glioma; Male; Rats; Rats, Sprague-Dawley; Temozolomide; Tetrahydroisoquinolines; Tissue Culture Techniques; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Survival; Temozolomide; Treatment Outcome | 2009 |
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Retrospective Studies; Survival Rate; Temozolomide | 2009 |
[Diagnostic and treatment delays do not modify the treatment outcome of patients with multiform glioblastoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Female; France; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Temozolomide; Time Factors; Treatment Outcome; Waiting Lists | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Senescence; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Dacarbazine; DNA Methylation; Glioma; Heterochromatin; Histones; Humans; Methyl-CpG-Binding Protein 2; Temozolomide | 2009 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Therapy, Combination; Female; Glioma; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Temozolomide | 2010 |
In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Dacarbazine; Genetic Therapy; Genetic Vectors; Guanine; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Lentivirus; Macaca mulatta; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide | 2009 |
Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Temozolomide | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; DNA Methylation; Epigenesis, Genetic; Female; Genomic Imprinting; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Temozolomide | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models, Animal; Drug Administration Routes; Drug Therapy, Combination; Female; Glioma; Rats; Rats, Inbred F344; Survival Analysis; Temozolomide; Xenograft Model Antitumor Assays | 2010 |
Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biocompatible Materials; Carmustine; Dacarbazine; Decanoic Acids; Drug Carriers; Humans; Polyesters; Temozolomide; Treatment Outcome | 2010 |
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carmustine; Cell Adhesion; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; Dacarbazine; DNA Primers; DNA, Complementary; Exons; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Transplantation, Heterologous; Treatment Outcome | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Brain Neoplasms; Carmustine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Drug Carriers; Female; France; Glioma; Humans; Male; Middle Aged; Polyesters; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Craniotomy; Dacarbazine; Glioblastoma; Humans; Magnetic Resonance Imaging; Retreatment; Temozolomide; Treatment Outcome | 2010 |
Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Guanine; Humans; Hydrazines; Mice; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Temozolomide | 2010 |
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Drug Implants; Female; Glioblastoma; Humans; Karnofsky Performance Status; Male; Middle Aged; Nervous System Diseases; Risk Factors; Survival Analysis; Temozolomide; Treatment Outcome | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Linear Models; Male; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Proportional Hazards Models; Radiotherapy Dosage; Reoperation; Retreatment; Salvage Therapy; Temozolomide; Time Factors; Young Adult | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioma; Hospitals; Humans; Incidence; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2010 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Proteins; Retrospective Studies; Survival Analysis; Temozolomide; Thrombocytopenia; Tumor Burden; Tumor Suppressor Proteins; Young Adult | 2012 |
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2011 |
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma].
Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmustine; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Histiocytosis, Langerhans-Cell; Hodgkin Disease; Humans; Ifosfamide; Incidental Findings; Lung Diseases; Lymphatic Diseases; Marijuana Smoking; Melphalan; Methylprednisolone; Mitoguazone; Remission Induction; Smoking; Tomography, X-Ray Computed; Vinblastine; Vindesine; Vinorelbine; Young Adult | 2011 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherap
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; DNA Methylation; Female; Glioblastoma; Humans; Male; Middle Aged; O(6)-Methylguanine-DNA Methyltransferase; Prognosis; Promoter Regions, Genetic; Temozolomide | 2012 |
Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neurosurgical Procedures; Polyesters; Survival Analysis; Temozolomide; Treatment Outcome | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine | 2012 |
In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model.
Topics: Animals; Carmustine; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Dogs; Genetic Therapy; Glioblastoma; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Lentivirus; Temozolomide; Transplantation Conditioning; Tumor Suppressor Proteins | 2012 |
The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; Dacarbazine; Decanoic Acids; Delayed-Action Preparations; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Polyesters; Temozolomide; Treatment Outcome | 2012 |
Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide; Treatment Outcome | 2012 |
Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Dacarbazine; Eukaryotic Translation Initiation Factor 5A; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioblastoma; Guanine; Humans; Lysine; Male; Mixed Function Oxygenases; Molecular Targeted Therapy; Neoplasm Grading; Oxidoreductases Acting on CH-NH Group Donors; Peptide Initiation Factors; RNA-Binding Proteins; Temozolomide | 2012 |
F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carmustine; Cell Survival; Cloning, Molecular; Cytoprotection; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Genetic Vectors; Hematopoietic Stem Cells; HL-60 Cells; Humans; K562 Cells; Lentivirus; Nimustine; Paclitaxel; Peptides; Real-Time Polymerase Chain Reaction; Temozolomide; Transgenes; Tumor Suppressor Proteins | 2012 |
Targeted nitric oxide delivery preferentially induces glioma cell chemosensitivity via altered p53 and O(6) -methylguanine-DNA methyltransferase activity.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Resistance, Neoplasm; Glioblastoma; Humans; Nitric Oxide; O(6)-Methylguanine-DNA Methyltransferase; Scorpion Venoms; Temozolomide; Tumor Suppressor Protein p53 | 2013 |
Effective elimination of cancer stem cells by a novel drug combination strategy.
Topics: Adenosine Triphosphate; Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA Damage; DNA Repair; Drug Combinations; Drug Synergism; Glioblastoma; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Hydrocarbons, Brominated; Hypoxia; Mice; Mice, SCID; Mitochondria; Neoplastic Stem Cells; Propionates; Temozolomide | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Drug Implants; Feasibility Studies; Female; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Postoperative Complications; Prospective Studies; Supratentorial Neoplasms; Survival Analysis; Survival Rate; Temozolomide | 2013 |
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustine; Chemoradiotherapy; Cisplatin; Cohort Studies; Cytarabine; Dacarbazine; Dexamethasone; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vinblastine; Young Adult | 2015 |
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Topics: Aminooxyacetic Acid; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glutamine; HEK293 Cells; Humans; Isocitrate Dehydrogenase; Mutation; Oxidative Stress; RNA, Small Interfering; Signal Transduction; Temozolomide | 2013 |
Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cryopreservation; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gene Dosage; Glial Fibrillary Acidic Protein; Glioblastoma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Temozolomide; Tumor Cells, Cultured; Vincristine | 2013 |
Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Glioblastoma; Guanosine; Humans; Methylation; Middle Aged; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Temozolomide | 2013 |
Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Glioblastoma; Humans; Middle Aged; Neoplasm Recurrence, Local; Postoperative Complications; Prognosis; Retrospective Studies; Temozolomide | 2014 |
Cool-1-mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Flow Cytometry; Glioblastoma; HEK293 Cells; Humans; Male; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Binding; Proto-Oncogene Proteins c-cbl; Rho Guanine Nucleotide Exchange Factors; RNA Interference; Signal Transduction; Spheroids, Cellular; Temozolomide; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured | 2014 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambucil; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Melphalan; Multicenter Studies as Topic; Neoplasm Staging; Prednisolone; Prednisone; Procarbazine; Prognosis; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vincristine | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbazine; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Glioma; Humans; Neoplasm Grading; Temozolomide | 2014 |
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Child, Preschool; Cytarabine; Dacarbazine; Doxorubicin; England; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Infant; Melphalan; Menopause, Premature; Ovary; Poisson Distribution; Proportional Hazards Models; Radiotherapy Dosage; Risk Assessment; Surveys and Questionnaires; Vinblastine; Wales; Young Adult | 2014 |
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genes, p53; Glioblastoma; Humans; Mice, Inbred C57BL; MutS Homolog 2 Protein; Radiation, Ionizing; Survival Analysis; Temozolomide; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Carmustine; Dacarbazine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioma; Inhibitory Concentration 50; Oxidative Stress; Rats; Temozolomide | 2015 |
MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carmustine; Chemoradiotherapy; Dacarbazine; Decanoic Acids; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Japan; Karnofsky Performance Status; Male; Middle Aged; Polyesters; Prognosis; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2015 |
Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Caspase 8; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Female; Glioblastoma; Humans; Luteolin; Mice; Mice, Nude; MicroRNAs; Signal Transduction; Silybin; Silymarin; Sirolimus; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; Glioblastoma; Humans; Nuclear Proteins; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Temozolomide; Transcription Factors | 2016 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Synergism; Female; Glioma; Glucose; Glucose Transport Proteins, Facilitative; Humans; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2017 |
A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; Craniotomy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Postoperative Complications; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Serbia; Survival Analysis; Temozolomide | 2017 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma; Carmustine; Child; Child, Preschool; Cranial Irradiation; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Endocrinology; Europe; Female; Humans; Ki-67 Antigen; Male; Middle Aged; Neoplasm Invasiveness; Neurosurgical Procedures; Pituitary Neoplasms; Societies, Medical; Surveys and Questionnaires; Temozolomide; Thalidomide; Tumor Suppressor Proteins; Young Adult | 2018 |
Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Cysts; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Implants; Drug Synergism; Female; Follow-Up Studies; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Neurosurgical Procedures; Postoperative Hemorrhage; Proportional Hazards Models; Retrospective Studies; Temozolomide; Treatment Outcome; Tumor Microenvironment | 2018 |
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dacarbazine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Kaplan-Meier Estimate; Male; Melphalan; Methylprednisolone; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Young Adult | 2018 |